Physician Assistant in Lake Zurich, IL Accepting Medicare
7 Physician Assistant nurses found. Showing 1 - 7
 Inna Dilman, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 900 W Il Route 22, Lake Zurich, IL 60047 Phone: 847-462-1700 |
Kathy M Vanbrunt, PA Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 15 S Old Rand Rd, Lake Zurich, IL 60047 Phone: 847-438-2144 Fax: 847-438-1597 |
Mary Mueller, PA Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 15 S Old Rand Rd, Lake Zurich, IL 60047 Phone: 847-438-2144 Fax: 847-438-1597 |
Robin M Fischer, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 900 W Il Route 22 Ste 100, Lake Zurich, IL 60047 Phone: 847-462-1700 |
Joyce Wood, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 350 Surryse Rd, Suite 100, Lake Zurich, IL 60047 Phone: 847-438-2144 Fax: 847-719-0335 |
Ms. Kristine Elizabeth Burgess, MS, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 350 Surryse Rd, Suite 100, Lake Zurich, IL 60047 Phone: 847-438-2144 Fax: 847-719-0335 |
 Mr. Craig Allen Baumgartner, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1 Golfview Rd, Suite 101, Lake Zurich, IL 60047 Phone: 847-726-4444 |
News Archive
Royal DSM to acquire Martek for $1,087 million
Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.
FDA approves new drug to treat hypoactive sexual desire disorder in premenopausal women
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas
Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.
Deaths caused by cardiovascular disease have decreased over the last 50 years
Adults with diabetes have experienced a 50 percent decline in the incidence rate for cardiovascular disease events in recent decades, according to a report in the November 24 issue of JAMA.
› Verified 5 days ago